Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
The assay has a very good sensitivity (detection limit for 17β-estradiol in the YES assay about 5 × 10−12 M or 1.4 ng/L), and the microplate format requires only small amounts of sample. Analysis of native aqueous samples, concentrated environmental samples and chemicals or mixtures in solvents like ethanol or DMSO is possible. Results can be obtained as quickly as after an overnight exposure. The handling of yeast cells is generally less demanding than mammalian cell culture. No international standards are available to date. An ISO guideline for the YES assay is under preparation. Saliva hormone testing
SPATT was introduced in 2004 as a method of monitoring aquatic toxins. This tool is able to adsorb toxins generated by microalgae or cyanobacteria, known as cyanotoxins. The adsorption is passive, and the biotoxins adhere to porous, resin filled sachets, or SPATT bags where they are then physically removed and examined. SPATT is a useful tool in tracking algal blooms as it is reliable, sensitive, and inexpensive. It has the ability to quickly alert the existence of aquatic toxins which prevents it from bioaccumulating in marine life. One of the downsides is that it does not give very good results for water-soluble toxins as compared to hydrophobic compounds. This tool is mainly used to determine intercellular concentrations of toxins but the cyanobacteria can also be lysed to determine the total toxin amount in a sample. Other drawbacks, such as a lack in calibration and the ability to only monitor dissolved toxins, make it difficult for this tool to be implemented in a more widespread manner. However, SPATT devices are able to detect many lipophilic and hydrophilic toxins that are linked to harmful algal bloom.
== See also == All pages with titles beginning with Combine All pages with titles containing Combine Combination (disambiguation) Combined (disambiguation) Combiner CombineZ, image processing software Merge (disambiguation) Unite (disambiguation)
==== Tax deduction for qualified tip income ==== The law creates new tax deductions for tips of up to $25,000 per year received by workers earning less than $150,000, with the tax deduction set to expire in 2028. In order to be eligible, a tip must be paid voluntarily by the payor, and the payor must determine the amount of the tip. The payor must not be subject to a penalty if they do not pay a tip, and the tips must not be subject to any negotiation. The tip must be given to workers working one of 68 different job types. Tips received while performing a service that is a felony or misdemeanor are not eligible. Tips received for prostitution or pornography are not eligible. Tips received as part of a tip pool are generally eligible. Tips received directly by a supervisor or manager are eligible only if they are for services they provided in a qualified occupation and not as part of a tip pool. If the customer is charged a service charge or an automatic tip amount that is not voluntary on the part of the customer, then the service charge or tip is not eligible. This includes if the company requires a customer to pay a service charge or a particular tip amount on parties greater than a certain size. Voluntary tips above such a minimum or mandatory charge are eligible. Recommended tips are eligible if they are optional on the part of the payer. If the customer is required to select a tip amount but does not have the option to choose to not tip at all, the minimum possible tip amount is not eligible but any tips exceeding that minimum are eligible.
Sources: en.wikipedia.org
In October 2016, IFFSI changed its name to Shakey's Pizza Asia Ventures Inc. (SPAVI) and became listed in the Philippine Stock Exchange on December 15, 2016 with the ticker symbol PSE: PIZZA. It was disclosed that IFFSI acquired ownership of the Shakey's trademark in the Philippines since 1999 and also owns the trademark rights for the Middle East, Asia (except Japan and Malaysia), China, India, Australia and New Zealand. Circa 2017, it signed a joint venture deal to bring the brand to Kuwait. SPAVI has garnered several recognitions over time. The company ranked in Financial Times' feature on Asia-Pacific's 500 high-growth companies in 2020 and 2021. It was also hailed as the "Philippines' Best Small Cap Company" by Finance Asia in 2018.
Sumatriptan, sold under the brand name Imitrex among others, is a medication used to treat migraine headaches and cluster headaches. It is taken orally, intranasally, or by subcutaneous injection. Therapeutic effects generally occur within three hours. Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist (triptan). The drug acts as a serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptor agonist and its common side effects include chest pressure, fatigue, vomiting, tingling, and vertigo. Serious side effects may include serotonin syndrome, heart attack, stroke, and seizures. With excessive use, medication overuse headaches may occur. It is unclear if use during pregnancy or breastfeeding is safe. The mechanism of action is not entirely clear. It is in the triptan class of medications. Sumatriptan was patented in 1982 and approved for medical use in 1992. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 107th most commonly prescribed medication in the United States, with more than 6 million prescriptions. It is also available as the combination product sumatriptan/naproxen.
=== Hydrolysis === DBNPA undergoes rapid pH-dependent hydrolysis in aqueous environments, leading to the formation of different degradation products. The C-Br bonds break down rapidly into smaller organic and inorganic byproducts when exposed to neutral to alkaline environments due to nucleophilic substitution. DBNPA can endure longer in acidic settings since the hydrolysis rate is lower. The pH has a significant impact on DBNPA's breakdown. The main degradation product at pH 5 is dibromoacetic acid (DBAA), which makes up 30.6% of all DBNPA breakdown products. The breakdown mechanism changes as the pH rises, favouring the synthesis of dibromoacetonitrile (DBAN), which dominates at pH 7 (54.5%) and pH 9 (38.6%). Ammonia, carbon dioxide, bromide ions, and cyanoacetic acid are produced by further hydrolysis in neutral or slightly alkaline conditions.
=== Recurring === Kaitlin Olson as Deborah "DJ" Vance Jr., Deborah's daughter who sells personal crafts Chris McDonald as Marty Ghilain, CEO of the Palmetto Casino Paul W. Downs as Jimmy LuSaque Jr., Deborah and Ava's manager Rose Abdoo as Josefina, Deborah's house manager Lorenza Izzo as Ruby, Ava's ex-girlfriend and an actress Megan Stalter as Kayla Schaeffer, Jimmy's inept assistant and boss's daughter Mark Indelicato as Damien, Deborah's personal assistant Poppy Liu as Kiki, Deborah's personal blackjack dealer and an employee at the Palmetto Johnny Sibilly as Wilson, a Vegas public water inspector and Marcus' love interest Angela E. Gibbs as Robin, Marcus' mother Jane Adams as Nina Daniels, Ava's mother Louis Herthum as Dennis Daniels, Ava's father who is recovering from a stroke Amanda Payton as Jackie, one of DJ's friends Joe Mande as Ray, a front desk clerk at the Palmetto Danielle Schneider as Rina, Marty's assistant Lauren Weedman as Jo Pezzimenti, the mayor of Las Vegas
==== Shoulder disorders ==== A 2014 Cochrane review found insufficient evidence to determine whether electrotherapy was better than exercise at treating adhesive capsulitis. As of 2004, there is insufficient evidence to draw conclusions about any intervention for rotator cuff pathology, including electrotherapy; furthermore, methodological problems precluded drawing conclusions about the efficacy of any rehabilitation method for impingement syndrome.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.